Knight Therapeutics Inc.
GUD.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 275.81M | 268.06M | 270.92M | 256.26M | 249.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 275.81M | 268.06M | 270.92M | 256.26M | 249.38M |
| Cost of Revenue | 157.28M | 147.34M | 143.57M | 132.59M | 128.75M |
| Gross Profit | 118.53M | 120.72M | 127.35M | 123.68M | 120.63M |
| SG&A Expenses | 77.74M | 73.52M | 72.50M | 68.33M | 66.79M |
| Depreciation & Amortization | 30.15M | 30.92M | 32.39M | 32.96M | 33.32M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 282.08M | 268.40M | 265.43M | 248.72M | 243.49M |
| Operating Income | -6.28M | -340.00K | 5.49M | 7.54M | 5.89M |
| Income Before Tax | -5.49M | 6.31M | 1.29M | -23.55M | -17.37M |
| Income Tax Expenses | -5.62M | -1.52M | -1.65M | -945.40K | -1.84M |
| Earnings from Continuing Operations | 0.13 | 7.83 | 2.94 | -22.61 | -15.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 130.90K | 7.83M | 2.94M | -22.61M | -15.52M |
| EBIT | -6.28M | -340.00K | 5.49M | 7.54M | 5.89M |
| EBITDA | 27.12M | 33.90M | 40.99M | 42.16M | 40.90M |
| EPS Basic | 0.00 | 0.08 | 0.03 | -0.22 | -0.15 |
| Normalized Basic EPS | 0.03 | 0.07 | 0.10 | 0.03 | 0.06 |
| EPS Diluted | -0.01 | 0.07 | 0.02 | -0.22 | -0.16 |
| Normalized Diluted EPS | 0.03 | 0.07 | 0.10 | 0.03 | 0.06 |
| Average Basic Shares Outstanding | 400.94M | 402.64M | 404.17M | 407.35M | 412.47M |
| Average Diluted Shares Outstanding | 401.78M | 403.48M | 404.58M | 407.35M | 412.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |